BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology 2020;72:1605-16. [PMID: 32043613 DOI: 10.1002/hep.31173] [Cited by in Crossref: 149] [Cited by in F6Publishing: 108] [Article Influence: 74.5] [Reference Citation Analysis]
Number Citing Articles
1 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
2 Younossi ZM, Pham H, Felix S, Stepanova M, Jeffers T, Younossi E, Allawi H, Lam B, Cable R, Afendy M, Younoszai Z, Afendy A, Rafiq N, Alzubaidi N, Ousman Y, Bailey M, Chris Z, Castillo-Catoni M, Fozdar P, Ramirez M, Husain M, Hudson E, Schneider I, Golabi P, Nader F. Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. Clin Transl Gastroenterol 2021;12:e00340. [PMID: 33825721 DOI: 10.14309/ctg.0000000000000340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Bacil GP, Cogliati B, Cardoso DR, Barbisan LF, Romualdo GR. Are isothiocyanates and polyphenols from Brassicaceae vegetables emerging as preventive/therapeutic strategies for NAFLD? The landscape of recent preclinical findings. Food Funct 2022. [PMID: 35899794 DOI: 10.1039/d2fo01488b] [Reference Citation Analysis]
4 Frost KL, Marie S, Cherrington NJ. Mechanistic Basis of Increased Susceptibility to Nephrotoxicants in Chronic Liver Disease. Current Opinion in Toxicology 2022. [DOI: 10.1016/j.cotox.2022.100347] [Reference Citation Analysis]
5 Pose E, Pera G, Torán P, Gratacós-Ginès J, Avitabile E, Expósito C, Díaz A, Graupera I, Rubio AB, Ginès P, Fabrellas N, Caballeria L. Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. Liver Int 2021;41:1556-64. [PMID: 33595176 DOI: 10.1111/liv.14830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hoene M, Kappler L, Kollipara L, Hu C, Irmler M, Bleher D, Hoffmann C, Beckers J, Hrabě de Angelis M, Häring HU, Birkenfeld AL, Peter A, Sickmann A, Xu G, Lehmann R, Weigert C. Exercise prevents fatty liver by modifying the compensatory response of mitochondrial metabolism to excess substrate availability. Mol Metab 2021;:101359. [PMID: 34695608 DOI: 10.1016/j.molmet.2021.101359] [Reference Citation Analysis]
7 Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. Hepatol Commun. [DOI: 10.1002/hep4.1765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhu Y, Xu J, Zhang X, Ke Y, Fu G, Guo Q. A low follicle-stimulating hormone level is a protective factor for non-alcoholic fatty liver disease in older men aged over 80. BMC Geriatr 2021;21:544. [PMID: 34641807 DOI: 10.1186/s12877-021-02490-6] [Reference Citation Analysis]
9 Zheng M, Fang W, Yu M, Ding R, Zeng H, Huang Y, Mi Y, Duan C. IL-6 and IL-10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis. BMC Endocr Disord 2021;21:242. [PMID: 34886817 DOI: 10.1186/s12902-021-00906-3] [Reference Citation Analysis]
10 Abeysekera KWM, Macpherson I, Glyn-owen K, Mcpherson S, Parker R, Harris R, Yeoman A, Rowe IA, Dillon JF. Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00020-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00261-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
12 Delik A, Dinçer S, Ülger Y, Akkız H, Karaoğullarından Ü. Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease. Gene 2022;833:146587. [PMID: 35598686 DOI: 10.1016/j.gene.2022.146587] [Reference Citation Analysis]
13 Lazarus JV, Palayew A, Carrieri P, Ekstedt M, Marchesini G, Novak K, Ratziu V, Romero-Gómez M, Tacke F, Zelber-Sagi S, Cortez-Pinto H, Anstee QM. European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease? JHEP Rep 2021;3:100234. [PMID: 33733078 DOI: 10.1016/j.jhepr.2021.100234] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
14 Luo L, Ye J, Shao C, Lin Y, Sun Y, Feng S, Wang W, Zhong B. Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection. Nutrients 2022;14:2114. [DOI: 10.3390/nu14102114] [Reference Citation Analysis]
15 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Metabolism 2021;122:154822. [PMID: 34289945 DOI: 10.1016/j.metabol.2021.154822] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
16 Giammarino AM, Qiu H, Bulsara K, Khan S, Jiang Y, Da BL, Bernstein DE, Satapathy SK. Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis. Hepatol Commun 2021. [PMID: 34668658 DOI: 10.1002/hep4.1831] [Reference Citation Analysis]
17 Yao MJ, Wang LJ, Liu S, Lu FM. Application of serum Golgi protein-73 in the management of chronic liver disease. Chin Med J (Engl) 2020;134:777-9. [PMID: 33323825 DOI: 10.1097/CM9.0000000000001296] [Reference Citation Analysis]
18 Welle CL, Olson MC, Reeder SB, Venkatesh SK. Magnetic Resonance Imaging of Liver Fibrosis, Fat, and Iron. Radiologic Clinics of North America 2022. [DOI: 10.1016/j.rcl.2022.04.003] [Reference Citation Analysis]
19 Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatol Int 2022. [PMID: 35666390 DOI: 10.1007/s12072-022-10365-0] [Reference Citation Analysis]
20 Jiang W, Mao X, Liu Z, Zhang T, Jin L, Chen X. Global Burden of Nonalcoholic Fatty Liver Disease, 1990 to 2019: Findings From the Global Burden of Disease Study 2019. J Clin Gastroenterol 2022. [PMID: 35921320 DOI: 10.1097/MCG.0000000000001739] [Reference Citation Analysis]
21 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
22 Ai J, Wang J, Liu D, Xiang H, Guo Y, Lv J, Zhang Q, Li J, Zhang X, Li Q, Liang J, Guo X, Feng Y, Liu L, Zhang X, Qin W, Wang X, Rao W, Zhang Q, Tian Q, Zhang Y, Xie F, Jiang S, Yan Y, Qiu Y, Wu H, Hou Z, Zhang N, Zhang A, Ji J, Yang J, Huang J, Zhao Z, Gu Y, Bian L, Zhang Z, Zou S, Ji H, Ge G, Du X, Hou A, Zhu Y, Cong Q, Xu J, Zu H, Wang Y, Yan Z, Yan X, BianBa Y, Ci Q, Zhang L, Yang S, Gao X, Zhong L, He S, Liu C, Huang Y, Liu Y, Xu D, Zhu Q, Xu X, Lv M, Zhang W, Qi X. Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases (CHESS-NMCID 2101): A multicenter study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01346-X. [PMID: 34942370 DOI: 10.1016/j.cgh.2021.12.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
23 Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguchi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00719-9. [PMID: 34229038 DOI: 10.1016/j.cgh.2021.06.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
24 Rivera-Andrade A, Petrick JL, Alvarez CS, Graubard BI, Florio AA, Kroker-Lobos MF, Parisi D, Freedman ND, Lazo M, Guallar E, Groopman JD, Ramirez-Zea M, McGlynn KA. Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala. Aliment Pharmacol Ther 2022;56:321-9. [PMID: 35484638 DOI: 10.1111/apt.16948] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
25 Zhao S, Wang Y, Wu W, Yang S, Feng L, Tao F, Ge W, Shen M, Xu W. Nonalcoholic fatty liver disease and risk of prostatic diseases: Roles of insulin resistance. Andrologia 2021;53:e14060. [PMID: 33782980 DOI: 10.1111/and.14060] [Reference Citation Analysis]
26 Guigas B, Jourdan T, Stienstra R. Editorial: Immune Regulation of Metabolic Homeostasis. Front Endocrinol (Lausanne) 2022;13:929460. [PMID: 35712253 DOI: 10.3389/fendo.2022.929460] [Reference Citation Analysis]
27 Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00567-X. [PMID: 34033923 DOI: 10.1016/j.cgh.2021.05.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 21.0] [Reference Citation Analysis]
28 Liao C, Huang P, Chien H, Lin T, Yeh C, Lin K. Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. Biomedicines 2022;10:1232. [DOI: 10.3390/biomedicines10061232] [Reference Citation Analysis]
29 Drożdż K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J, Lip GYH. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. Nutrients 2021;14:103. [PMID: 35010976 DOI: 10.3390/nu14010103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Zou ZY, Zeng J, Ren TY, Shi YW, Yang RX, Fan JG. Efficacy of Intragastric Balloons in the Markers of Metabolic Dysfunction-associated Fatty Liver Disease: Results from Meta-analyses. J Clin Transl Hepatol 2021;9:353-63. [PMID: 34221921 DOI: 10.14218/JCTH.2020.00183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Waghorn PA, Ferreira DS, Erstad DJ, Rotile NJ, Masia R, Jones CM, Tu C, Sojoodi M, Chen YI, Schlerman F, Wellen J, Martinez RVP, Tanabe KK, Fuchs BC, Caravan P. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Sci Rep 2021;11:6105. [PMID: 33731798 DOI: 10.1038/s41598-021-85679-4] [Reference Citation Analysis]
32 Li Q, Li JF, Mao XR. Application of artificial intelligence in liver diseases: From diagnosis to treatment. Artif Intell Gastroenterol 2021; 2(5): 133-140 [DOI: 10.35712/aig.v2.i5.133] [Reference Citation Analysis]
33 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
34 Alam S, Fahim SM. Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease. World J Hepatol 2021; 13(10): 1203-1207 [PMID: 34786161 DOI: 10.4254/wjh.v13.i10.1203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 [DOI: 10.1101/2020.08.20.20176214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
37 Burra P, Ferrarese A. Transplanting severely obese cirrhotic patients: Heavy clouds still on the horizon. United European Gastroenterol J 2022. [PMID: 35474616 DOI: 10.1002/ueg2.12234] [Reference Citation Analysis]
38 Peschl V, Seitz T, Sommer J, Thasler W, Bosserhoff A, Hellerbrand C. Bone morphogenetic protein 13 in hepatic stellate cells and hepatic fibrosis. J Cell Biochem 2022. [PMID: 35442524 DOI: 10.1002/jcb.30248] [Reference Citation Analysis]
39 Martinez-castillo M, León-mancilla B, Ramírez-rico G, Alfaro A, Pérez-torres A, Díaz-infante D, García-loya J, Medina-avila Z, Sanchez-hernandez J, Piña-barba C, Gutierrez-reyes G. Xenoimplant of Collagen Matrix Scaffold in Liver Tissue as a Niche for Liver Cells. Front Med 2022;9:808191. [DOI: 10.3389/fmed.2022.808191] [Reference Citation Analysis]
40 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Tassachew Y, Abebe T, Belyhun Y, Teffera T, Shewaye AB, Desalegn H, Andualem H, Kinfu A, Mulu A, Mihret A, Howe R, Aseffa A. Prevalence of HIV and Its Co-Infection with Hepatitis B/C Virus Among Chronic Liver Disease Patients in Ethiopia. Hepat Med 2022;14:67-77. [PMID: 35591850 DOI: 10.2147/HMER.S365443] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Vopham T, Kim NJ, Berry K, Mendoza JA, Kaufman JD, Ioannou GN. PM2.5 air pollution exposure and nonalcoholic fatty liver disease in the Nationwide Inpatient Sample. Environmental Research 2022. [DOI: 10.1016/j.envres.2022.113611] [Reference Citation Analysis]
43 Huber Y, Schulz A, Schmidtmann I, Beutel M, Pfeiffer N, Münzel T, Galle PR, Wild PS, Lackner KJ, Schattenberg JM. Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany. Hepatol Commun 2022. [PMID: 35122404 DOI: 10.1002/hep4.1899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ciardullo S, Cannistraci R, Mazzetti S, Mortara A, Perseghin G. Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population. Front Endocrinol (Lausanne) 2021;12:711484. [PMID: 34381424 DOI: 10.3389/fendo.2021.711484] [Reference Citation Analysis]
45 Zhu Y, Ke Y, Hu Y, Wu K, Liu S, Hu J. Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis 2022;21:57. [PMID: 35780150 DOI: 10.1186/s12944-022-01658-2] [Reference Citation Analysis]
46 Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01183-6. [PMID: 34768009 DOI: 10.1016/j.cgh.2021.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Hong T, Chen Y, Li X, Lu Y. The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. Oxid Med Cell Longev 2021;2021:6889533. [PMID: 34745420 DOI: 10.1155/2021/6889533] [Reference Citation Analysis]
48 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
49 Zhang X, Deng F, Zhang Y, Zhang X, Chen J, Jiang Y. PPARγ attenuates hepatic inflammation and oxidative stress of non‑alcoholic steatohepatitis via modulating the miR‑21‑5p/SFRP5 pathway. Mol Med Rep 2021;24:823. [PMID: 34558644 DOI: 10.3892/mmr.2021.12463] [Reference Citation Analysis]
50 Xu XL, Jiang LS, Wu CS, Pan LY, Lou ZQ, Peng CT, Dong Y, Ruan B. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool? J Formos Med Assoc 2021:S0929-6646(21)00344-2. [PMID: 34325952 DOI: 10.1016/j.jfma.2021.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology 2021;161:1030-1042.e8. [PMID: 34416976 DOI: 10.1053/j.gastro.2021.04.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
52 Nguyen VH, Yeo YH, Zou B, Le MH, Henry L, Cheung RC, Nguyen MH. Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD. J Intern Med 2021;289:840-50. [PMID: 33340186 DOI: 10.1111/joim.13203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Yezli S, Mushi A, Almuzaini Y, Balkhi B, Yassin Y, Khan A. Prevalence of Diabetes and Hypertension among Hajj Pilgrims: A Systematic Review. Int J Environ Res Public Health 2021;18:1155. [PMID: 33525524 DOI: 10.3390/ijerph18031155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, Ahmed A, Racila A, Henry L. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19:580-589.e5. [PMID: 32531342 DOI: 10.1016/j.cgh.2020.05.064] [Cited by in Crossref: 96] [Cited by in F6Publishing: 73] [Article Influence: 48.0] [Reference Citation Analysis]
55 De Pergola G, Castellana F, Zupo R, De Nucci S, Panza F, Castellana M, Lampignano L, Di Chito M, Triggiani V, Sardone R, Giannelli G. A family history of type 2 diabetes as a predictor of fatty liver disease in diabetes-free individuals with excessive body weight. Sci Rep 2021;11:24084. [PMID: 34916558 DOI: 10.1038/s41598-021-03583-3] [Reference Citation Analysis]
56 Swift O, Sharma S, Ramanarayanan S, Umar H, Laws KR, Vilar E, Farrington K. Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis. Clinical Kidney Journal 2021. [DOI: 10.1093/ckj/sfab230] [Reference Citation Analysis]
57 Huang TS, Wu IW, Lin CL, Shyu YC, Chen YC, Chien RN. Prognosis of Chronic Kidney Disease in Patients with Non-Alcoholic Fatty Liver Disease: a Northeastern Taiwan Community Medicine Research Cohort. Biomed J 2022:S2319-4170(22)00058-0. [PMID: 35460926 DOI: 10.1016/j.bj.2022.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021;6:578-88. [PMID: 33961787 DOI: 10.1016/S2468-1253(21)00020-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 51.0] [Reference Citation Analysis]
59 Zhang T, Xu J, Ye L, Lin X, Xu Y, Pan X, Weng X, Ye C, Fan L, Ren Y, Shan PF. Age, Gender and Geographic Differences in Global Health Burden of Cirrhosis and Liver Cancer due to Nonalcoholic Steatohepatitis. J Cancer 2021;12:2855-65. [PMID: 33854586 DOI: 10.7150/jca.52282] [Reference Citation Analysis]
60 Arshad T, Paik JM, Biswas R, Alqahtani SA, Henry L, Younossi ZM. Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. Hepatol Commun 2021;5:1676-88. [PMID: 34558817 DOI: 10.1002/hep4.1760] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Rusyn I, Arzuaga X, Cattley RC, Corton JC, Ferguson SS, Godoy P, Guyton KZ, Kaplowitz N, Khetani SR, Roberts RA, Roth RA, Smith MT. Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity. Hepatology 2021;74:3486-96. [PMID: 34105804 DOI: 10.1002/hep.31999] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
62 Loomba R, Ratziu V, Harrison SA; NASH Clinical Trial Design International Working Group. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. Gastroenterology 2021:S0016-5085(21)03795-1. [PMID: 34822801 DOI: 10.1053/j.gastro.2021.10.051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
63 Huang DQ, Singal AG, Kono Y, Tan DJ, El-serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism 2022. [DOI: 10.1016/j.cmet.2022.05.003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Skladany L, Molcan P, Vnencakova J, Vrbova P, Kukla M, Laffers L, Koller T. Frailty in Nonalcoholic Fatty Liver Cirrhosis: A Comparison with Alcoholic Cirrhosis, Risk Patterns, and Impact on Prognosis. Can J Gastroenterol Hepatol 2021;2021:5576531. [PMID: 34095016 DOI: 10.1155/2021/5576531] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
65 Deng YF, Xu QQ, Chen TQ, Ming JX, Wang YF, Mao LN, Zhou JJ, Sun WG, Zhou Q, Ren H, Zhang YH. Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway. Phytomedicine 2022;104:154241. [PMID: 35749827 DOI: 10.1016/j.phymed.2022.154241] [Reference Citation Analysis]
66 Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28:528-62. [PMID: 35569886 DOI: 10.1016/j.eprac.2022.03.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
67 Younossi ZM, Stepanova M, Lam B, Cable R, Felix S, Jeffers T, Younossi E, Pham H, Srishord M, Austin P, Estep M, Terra K, Escheik C, de Avila L, Golabi P, Kolacevski A, Racila A, Henry L, Gerber L. Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. Hepatol Commun 2021. [PMID: 34558853 DOI: 10.1002/hep4.1802] [Reference Citation Analysis]
68 Younossi ZM, Henry L. Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH). Endocr Pract 2021:S1530-891X(21)01417-8. [PMID: 34952219 DOI: 10.1016/j.eprac.2021.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Li W, Kemos P, Salciccioli JD, Marshall DC, Shalhoub J, Alazawi W. Socioeconomic Factors Associated With Liver-Related Mortality From 1985 to 2015 in 36 Developed Countries. Clin Gastroenterol Hepatol 2021;19:1698-1707.e13. [PMID: 32835839 DOI: 10.1016/j.cgh.2020.08.047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
70 Gidener T, Yin M, Dierkhising RA, Allen AM, Ehman RL, Venkatesh SK. Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study. Hepatology 2022;75:379-90. [PMID: 34510513 DOI: 10.1002/hep.32151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
71 Muthuramalingam K, Kim Y, Cho M. β-glucan, "the knight of health sector": critical insights on physiochemical heterogeneities, action mechanisms and health implications. Crit Rev Food Sci Nutr 2021;:1-37. [PMID: 33819119 DOI: 10.1080/10408398.2021.1908221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Zhou Y, Wu C, Wang X, Li P, Fan N, Zhang W, Liu Z, Zhang W, Tang B. Exploring the Changes of Peroxisomal Polarity in the Liver of Mice with Nonalcoholic Fatty Liver Disease. Anal Chem 2021;93:9609-20. [PMID: 34191493 DOI: 10.1021/acs.analchem.1c01776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Stahmeyer JT, Hemmerling M, Burger B, Eberhard S, Krauth C, Zeidler J, Herr A, Weseloh H, Rossol S. [Frequency of diagnosed non-alcololic fatty liver disease (NAFLD) in the German population - An analysis based on health insurance data]. Z Gastroenterol 2021;59:851-8. [PMID: 33757144 DOI: 10.1055/a-1402-1263] [Reference Citation Analysis]
74 Zou B, Yeo YH, Cheung R, Ingelsson E, Nguyen MH. Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. Dig Dis Sci 2021;66:2092-100. [PMID: 33782808 DOI: 10.1007/s10620-021-06954-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
75 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Mori M, Izawa T, Inai Y, Fujiwara S, Aikawa R, Kuwamura M, Yamate J. Dietary Iron Overload Differentially Modulates Chemically-Induced Liver Injury in Rats. Nutrients 2020;12:E2784. [PMID: 32932999 DOI: 10.3390/nu12092784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
77 Ould Setti M, Voutilainen A, Tajik B, Niskanen L, Tuomainen TP. Negative interaction of fatty liver and hypertension on cardiovascular mortality in non-diabetic men: 34 years of follow-up. Scand J Gastroenterol 2021;56:1096-102. [PMID: 34362281 DOI: 10.1080/00365521.2021.1951836] [Reference Citation Analysis]
78 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
79 Tang R, Li R, Li H, Ma XL, Du P, Yu XY, Ren L, Wang LL, Zheng WS. Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease. ACS Nano 2021. [PMID: 34705426 DOI: 10.1021/acsnano.1c02158] [Reference Citation Analysis]
80 Wang M, Li J, Li H, Dong B, Jiang J, Liu N, Tan J, Wang X, Lei L, Li H, Sun H, Tang M, Wang H, Yan H, Li Y, Jiang J, Peng Z. Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:5544. [PMID: 35628360 DOI: 10.3390/ijms23105544] [Reference Citation Analysis]
81 Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. J Hepatol 2021:S0168-8278(21)00358-5. [PMID: 34081959 DOI: 10.1016/j.jhep.2021.05.022] [Reference Citation Analysis]
82 Jiao TY, Ma YD, Guo XZ, Ye YF, Xie C. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacol Sin 2022;43:1103-19. [PMID: 35217817 DOI: 10.1038/s41401-022-00880-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
83 Della Torre S. Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. Cells 2021;10:2502. [PMID: 34572151 DOI: 10.3390/cells10092502] [Reference Citation Analysis]
84 Howell J, Majumdar A, Fink M, Byrne M, Mccaughan G, Strasser SI, Crawford M, Hodgkinson P, Stuart KA, Tallis C, Chen J, Wigg A, Jones R, Jaques B, Jeffrey G, Adams L, Wallace MC, Gane E, Thompson A, Gow P. The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand. Transplantation Direct 2022;8:e1345. [DOI: 10.1097/txd.0000000000001345] [Reference Citation Analysis]
85 Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. Hepatol Commun 2020;4:1769-80. [PMID: 33305148 DOI: 10.1002/hep4.1599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
86 Yin K, Zhou X, Jiang W, Wang L, Dai Z, Tang B. Jiangzhi Ligan Decoction Inhibits GSDMD-Mediated Canonical/Noncanonical Pyroptosis Pathways and Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease. Dis Markers 2021;2021:9963534. [PMID: 34239622 DOI: 10.1155/2021/9963534] [Reference Citation Analysis]
87 Zupo R, Castellana F, Donghia R, Lampignano L, Guerra V, De Pergola G, Lozupone M, Bortone I, De Nucci S, Tatoli R, Tirelli S, Sborgia G, Giannelli G, Panza F, Sardone R. Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study. Geroscience 2021. [PMID: 34378088 DOI: 10.1007/s11357-021-00434-x] [Reference Citation Analysis]
88 Laursen TL, Kjær MB, Kristensen L, Grønbæk H. Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center. J Clin Med 2022;11:2271. [PMID: 35566397 DOI: 10.3390/jcm11092271] [Reference Citation Analysis]
89 Barchetta I, Cimini FA, Cavallo MG. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. Nutrients 2020;12:E3302. [PMID: 33126575 DOI: 10.3390/nu12113302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
90 Jones JG. Non-Invasive Analysis of Human Liver Metabolism by Magnetic Resonance Spectroscopy. Metabolites 2021;11:751. [PMID: 34822409 DOI: 10.3390/metabo11110751] [Reference Citation Analysis]
91 Catania R, Lopes Vendrami C, Bolster BD, Niemzcura R, Borhani AA, Miller FH. Intra-patient comparison of 3D and 2D magnetic resonance elastography techniques for assessment of liver stiffness. Abdom Radiol (NY) 2022;47:998-1008. [PMID: 34982182 DOI: 10.1007/s00261-021-03355-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Chen X, Wen H, Li Q, Shen L, Luo X, Zhou B, Guo R. Quantification of liver fat deposition in obese and diabetic patients: A pilot study on the correlation with myocardium and periapical fat content☆. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.005] [Reference Citation Analysis]
93 Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. The Lancet Diabetes & Endocrinology 2022;10:284-96. [DOI: 10.1016/s2213-8587(22)00003-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
94 Younossi ZM, Yilmaz Y, El-Kassas M, Duseja A, Hamid S, Esmat G, Méndez-Sánchez N, Chan WK, Singal AK, Lam B, Felix S, Younossi E, Verma M, Price JK, Nader F, Younossi I, Racila A, Stepanova M. The impact of the COVID-19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry. Hepatol Commun 2022. [PMID: 35880475 DOI: 10.1002/hep4.2048] [Reference Citation Analysis]
95 Song J, Kim H, Lee D, Min J, Lee YM, Kang M. Association between long working hours and liver enzymes: evidence from the Korea National Health and Nutrition Examination Survey, 2007–2017. Ann Occup Environ Med 2022;34:e9. [DOI: 10.35371/aoem.2022.34.e9] [Reference Citation Analysis]
96 Zhao ZH, Wang ZX, Zhou D, Han Y, Ma F, Hu Z, Xin FZ, Liu XL, Ren TY, Zhang F, Xue Y, Cui A, Liu Z, Bai J, Liu Y, Cai G, Su W, Dai X, Shen F, Pan Q, Li Y, Fan JG. Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene. Cell Mol Gastroenterol Hepatol 2021;12:857-71. [PMID: 33989817 DOI: 10.1016/j.jcmgh.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Antunes C, Arbo MD, Konrath EL. Hepatoprotective Native Plants Documented in Brazilian Traditional Medicine Literature: Current Knowledge and Prospects. Chem Biodivers 2022;19:e202100933. [PMID: 35421282 DOI: 10.1002/cbdv.202100933] [Reference Citation Analysis]
98 Li K, Tharwat M, Larson EL, Felgendreff P, Hosseiniasl SM, Rmilah AA, Safwat K, Ross JJ, Nyberg SL. Re-Endothelialization of Decellularized Liver Scaffolds: A Step for Bioengineered Liver Transplantation. Front Bioeng Biotechnol 2022;10:833163. [DOI: 10.3389/fbioe.2022.833163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Qayed E, Migdal AL, Jagannathan R, Miller LS, Pasquel FJ. Characteristics and Outcomes of Black and White Patients Hospitalized With Nonalcoholic Steatohepatitis: A Nationwide Analysis. J Clin Gastroenterol 2022. [PMID: 35357331 DOI: 10.1097/MCG.0000000000001698] [Reference Citation Analysis]
100 Ntandja Wandji LC, Ningarhari M, Lassailly G, Dharancy S, Boleslawski E, Mathurin P, Louvet A. Liver Transplantation in Alcohol-related Liver Disease and Alcohol-related Hepatitis. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.06.013] [Reference Citation Analysis]
101 Aboubakr EM, Mohammed HA, Hassan AS, Mohamed HB, El Dosoky MI, Ahmad AM. Glutathione-loaded non-ionic surfactant niosomes: A new approach to improve oral bioavailability and hepatoprotective efficacy of glutathione. Nanotechnology Reviews 2022;11:117-37. [DOI: 10.1515/ntrev-2022-0010] [Reference Citation Analysis]
102 Vahedi H, Atefi M, Entezari MH, Hassanzadeh A. The effect of sesame oil consumption compared to sunflower oil on lipid profile, blood pressure, and anthropometric indices in women with non-alcoholic fatty liver disease: a randomized double-blind controlled trial. Trials 2022;23:551. [PMID: 35804451 DOI: 10.1186/s13063-022-06451-1] [Reference Citation Analysis]
103 Ould Setti M, Voutilainen A, Tuomainen TP. Renal hyperfiltration, fatty liver index, and the hazards of all-cause and cardiovascular mortality in Finnish men. Epidemiol Health 2021;43:e2021001. [PMID: 33445827 DOI: 10.4178/epih.e2021001] [Reference Citation Analysis]
104 Fallowfield JA, Jimenez-Ramos M, Robertson A. Emerging synthetic drugs for the treatment of liver cirrhosis. Expert Opin Emerg Drugs 2021;26:149-63. [PMID: 33856246 DOI: 10.1080/14728214.2021.1918099] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Yang A, Zhu X, Zhang L, Zhang Y, Zhang D, Jin M, Niu J, Zhang H, Ding Y, Lv G. Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study. Hepatol Int 2022. [PMID: 35829866 DOI: 10.1007/s12072-022-10355-2] [Reference Citation Analysis]
106 Paik JM, Mir S, Alqahtani SA, Younossi Y, Ong JP, Younossi ZM. Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. Hepatol Commun 2021. [PMID: 34558838 DOI: 10.1002/hep4.1707] [Reference Citation Analysis]
107 Younossi ZM, Wong VW, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. Hepatol Commun 2020;4:1637-50. [PMID: 33163834 DOI: 10.1002/hep4.1581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
108 Xiao LS, Hu CY, Cui H, Li RN, Hong C, Li QM, Huang CY, Dong ZY, Zhu HB, Liu L. Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer Med 2022. [PMID: 35599583 DOI: 10.1002/cam4.4818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Subhani M, Sheth A, Ahmed J, Wijayasiri P, Gardezi SA, Enki D, Morling JR, Aithal GP, Ryder SD, Aravinthan AD. Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis. Thromb Res 2022;215:19-29. [PMID: 35594737 DOI: 10.1016/j.thromres.2022.05.004] [Reference Citation Analysis]
110 Jin L, Sun Y, Li Y, Zhang H, Yu W, Li Y, Xin Y, Alsareii SA, Wang Q, Zhang D. A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis. Peptides 2021;143:170597. [PMID: 34118361 DOI: 10.1016/j.peptides.2021.170597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Lu FB, Zheng KI, Rios RS, Targher G, Byrne CD, Zheng MH. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2020;35:2041-50. [PMID: 32573017 DOI: 10.1111/jgh.15156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
112 Yang HY, Wang D, Chen C, Liu Y, Han C, Gao Y, Li ZS, Liao Z, Hu LH. Global research status of gastroenterology and hepatology: A bibliometrics study. Medicine (Baltimore) 2021;100:e25291. [PMID: 33847628 DOI: 10.1097/MD.0000000000025291] [Reference Citation Analysis]
113 Jackson KG, Way GW, Zhou H. Bile acids and sphingolipids in non-alcoholic fatty liver disease. Chin Med J (Engl) 2022. [PMID: 35788089 DOI: 10.1097/CM9.0000000000002156] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Birnie E, Biemond JJ, Wiersinga WJ. Drivers of melioidosis endemicity: epidemiological transition, zoonosis, and climate change. Curr Opin Infect Dis 2022;35:196-204. [PMID: 35665713 DOI: 10.1097/QCO.0000000000000827] [Reference Citation Analysis]
115 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
116 Pan S, Yu Y, Wang S, Tu B, Shen Y, Qiu Q, Liu X, Su N, Zuo Y, Luan J, Zhang JY, Shi M, Meng F, Wang FS. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. Front Immunol 2022;13:892618. [PMID: 35711409 DOI: 10.3389/fimmu.2022.892618] [Reference Citation Analysis]
117 Boehlig A, Gerhardt F, Petroff D, van Boemmel F, Berg T, Blank V, Karlas T, Wiegand J. Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. Biomedicines 2022;10:451. [DOI: 10.3390/biomedicines10020451] [Reference Citation Analysis]
118 Kostallari E, Valainathan S, Biquard L, Shah VH, Rautou PE. Role of extracellular vesicles in liver diseases and their therapeutic potential. Adv Drug Deliv Rev 2021;175:113816. [PMID: 34087329 DOI: 10.1016/j.addr.2021.05.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
119 Ojeda-Granados C, Panduro A, Gonzalez-Aldaco K, Rivera-Iñiguez I, Campos-Medina L, Roman S. Adherence to a Fish-Rich Dietary Pattern Is Associated with Chronic Hepatitis C Patients Showing Low Viral Load: Implications for Nutritional Management. Nutrients 2021;13:3337. [PMID: 34684338 DOI: 10.3390/nu13103337] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZM. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology 2022;75:1204-17. [PMID: 34741554 DOI: 10.1002/hep.32228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
121 Stepanova M, Younossi Z. Reply. Clin Gastroenterol Hepatol 2021;19:1299-300. [PMID: 33248088 DOI: 10.1016/j.cgh.2020.07.038] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
122 Shroff H, VanWagner LB. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. Curr Hepatol Rep. 2020;19:315-326. [PMID: 33585157 DOI: 10.1007/s11901-020-00530-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Reference Citation Analysis]
124 López-gonzález ÁA, Altisench Jané B, Masmiquel Comas L, Arroyo Bote S, González San Miguel HM, Ramírez Manent JI. Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study. Nutrients 2022;14:2795. [DOI: 10.3390/nu14142795] [Reference Citation Analysis]
125 Amoako A, Ortiz-Paredes D, Engler K, Lebouché B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. Int J Drug Policy 2021;:103247. [PMID: 33853727 DOI: 10.1016/j.drugpo.2021.103247] [Reference Citation Analysis]
126 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
127 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020;69:1691-705. [PMID: 32321858 DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 130] [Cited by in F6Publishing: 96] [Article Influence: 65.0] [Reference Citation Analysis]
128 Moretti R, Giuffré M, Crocè LS, Gazzin S, Tiribelli C. Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia. J Pers Med 2022;12:1106. [PMID: 35887603 DOI: 10.3390/jpm12071106] [Reference Citation Analysis]
129 Zeng J, Fan JG. From NAFLD to MAFLD: Not just a change in the name. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00125-4. [PMID: 35613992 DOI: 10.1016/j.hbpd.2022.05.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Younossi ZM, Stepanova M, Younossi I, Racila A. Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV. J Viral Hepat 2021;28:484-92. [PMID: 33306234 DOI: 10.1111/jvh.13451] [Reference Citation Analysis]
131 Praharaj DL, Mallick B, Nath P, Gupta S, Anand AC. Knowledge, attitude and practice of Gastroenterologists and hepatologists regarding vaccination in patients with chronic liver disease. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.03.010] [Reference Citation Analysis]
132 Saed CT, Tabatabaei Dakhili SA, Ussher JR. Pyruvate Dehydrogenase as a Therapeutic Target for Nonalcoholic Fatty Liver Disease. ACS Pharmacol Transl Sci 2021;4:582-8. [PMID: 33860188 DOI: 10.1021/acsptsci.0c00208] [Reference Citation Analysis]
133 Younossi ZM, Harring M, Younossi Y, Ong JP, Alqahtani SA, Stepanova M. The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01131-9. [PMID: 34666156 DOI: 10.1016/j.cgh.2021.10.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Villeret F, Dumortier J, Erard-Poinsot D. How will NAFLD change the liver transplant landscape in the 2020s? Clin Res Hepatol Gastroenterol 2021;:101759. [PMID: 34311133 DOI: 10.1016/j.clinre.2021.101759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
135 Pang J, Chen K, Chen S, Chen X. Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990-2019: a systematic analysis for the GBD 2019. Diabetol Metab Syndr 2022;14:112. [PMID: 35941673 DOI: 10.1186/s13098-022-00885-y] [Reference Citation Analysis]
136 Julià H, Benaiges D, Pedro-botet J. Bariatric surgery and non-alcoholic fatty liver disease. Medicina Clínica 2022. [DOI: 10.1016/j.medcli.2021.12.003] [Reference Citation Analysis]
137 Paik JM, Younossi Y, Henry L, Mishra A, Younossi ZM. Recent Trends in the Global Burden of Hepatitis B Virus: 2007-2017. Gastroenterology 2021;160:1845-1846.e3. [PMID: 33421516 DOI: 10.1053/j.gastro.2020.11.057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Rodríguez M, González-Diéguez ML, Varela M, Cadahía V, Andrés-Vizán SM, Mesa A, Castaño A, Alvarez-Navascués C. Impact of Alcohol Abstinence on the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Cirrhosis. Am J Gastroenterol 2021. [PMID: 34569986 DOI: 10.14309/ajg.0000000000001399] [Reference Citation Analysis]
139 Gupta B, Rai R, Oertel M, Raeman R. Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. Semin Liver Dis 2022;42:122-37. [PMID: 35738255 DOI: 10.1055/s-0042-1748037] [Reference Citation Analysis]
140 Colombo M, Barouki R. Expanding the liver exposome: should hepatologists care about air pollution? J Hepatol 2021:S0168-8278(21)02165-6. [PMID: 34883156 DOI: 10.1016/j.jhep.2021.11.001] [Reference Citation Analysis]